Data Sheet (Cat.No.T8764)

TargetMol

PKC-iota inhibitor 1

Chemical Properties



CAS No. : 2328094-11-5

Formula: C21H22N6O

Molecular Weight: 374.44

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	PKC-iota inhibitor 1 is an inhibitor of protein kinase C-iota (PKC-ι ; IC50 : 0.34 μM)
Targets(IC50)	AMPK,PKC

Solubility Information

Solubility	DMSO: 125 mg/mL (333.83 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 10 mg/mL (26.71 mM),Solution. 10% DMSO+90% Saline: < 10 mg/mL (26.71 mM),Lower concentrations may be soluble, but exact solubility limit is unknown. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.6707 mL	13.3533 mL	26.7065 mL
5 mM	0.5341 mL	2.6707 mL	5.3413 mL
10 mM	0.2671 mL	1.3353 mL	2.6707 mL
50 mM	0.0534 mL	0.2671 mL	0.5341 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Kwiatkowski J, et al. Fragment-based Discovery of a Small-Molecule Protein Kinase C-iota Inhibitor Binding Post-kinase Domain Residues. ACS Med Chem Lett. 2019 Feb 15;10(3):318-323.

Jiao J, Ruan L, Cheng C, et al.Paired protein kinases PRKCI-RIPK2 promote pancreatic cancer growth and metastasis via enhancing NF-κB/JNK/ERK phosphorylation.Molecular Medicine.2023, 29(1): 1-17.